Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alector is a clinical-stage biotechnology company developing immuno-neurology therapeutics targeting neurodegeneration through innate immune modulation. The company's lead programs include latozinemab (AL001) for frontotemporal dementia and AL101 for progranulin-deficient diseases, with partnerships including GSK and AbbVie providing non-dilutive funding. With $0.2B market cap and negative cash flow of $200M annually, the stock trades on clinical trial readouts and partnership economics rather than current fundamentals.
Alector operates a partnership-driven biotech model, monetizing its immuno-neurology platform through upfront payments, milestone achievements, and future royalty streams from pharmaceutical partners. The company retains co-development and co-commercialization rights on select programs while receiving non-dilutive funding to advance clinical trials. Current revenue is entirely collaboration-based with no product sales; profitability depends on successful Phase 2/3 trial completion, regulatory approval, and commercial launch of pipeline assets targeting genetically-defined patient populations in frontotemporal dementia, Alzheimer's disease, and related neurodegenerative conditions. The 100% gross margin reflects the service-based nature of collaboration revenue with minimal direct costs.
Clinical trial data readouts for AL001 (latozinemab) in frontotemporal dementia - primary endpoint achievement drives 30-50% single-day moves
FDA regulatory interactions and breakthrough therapy designation decisions for lead programs
Partnership expansion announcements or milestone payment triggers from GSK/AbbVie collaborations
Cash runway updates and financing announcements given $200M annual burn rate against $0.2B market cap
Competitive developments in neurodegeneration space from larger biotechs (Biogen, Eisai, Eli Lilly)
Binary clinical trial risk - single Phase 3 failure in lead programs could render company value near-zero given limited pipeline diversity and high development costs in neurodegeneration
Regulatory pathway uncertainty for immuno-neurology mechanisms with limited precedent for FDA approval in frontotemporal dementia indications
Long development timelines (8-12 years from discovery to approval) in neurodegenerative diseases create sustained cash burn and dilution risk before potential commercialization
Large-cap pharmaceutical competition from Biogen, Eisai, Eli Lilly with greater resources and established neurology commercial infrastructure
Alternative mechanism approaches to neurodegeneration (anti-amyloid, tau-targeting, gene therapy) may prove more efficacious than innate immune modulation
Partnership dependency creates risk of program termination if GSK or AbbVie reprioritize portfolios or achieve better results with competing assets
Liquidity crisis risk - $200M annual cash burn against $0.2B market cap suggests potential need for dilutive financing within 12-18 months absent partnership milestones
Debt/equity ratio of 0.66 indicates existing leverage that constrains additional borrowing capacity for clinical-stage company with no product revenue
Current ratio of 3.76 provides near-term cushion but insufficient to fund multiple Phase 3 trials to completion without additional capital
low - Clinical trial timelines and regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact biotech financing availability and pharmaceutical partner willingness to fund early-stage programs. Patient enrollment may see modest delays during economic stress, but neurodegeneration trials targeting genetically-defined populations are less economically sensitive than discretionary healthcare.
Rising interest rates create significant headwinds through multiple channels: (1) higher discount rates compress NPV of distant cash flows from potential product approvals 5-7 years out, (2) reduced risk appetite among biotech investors shifts capital away from speculative clinical-stage names toward profitable growth companies, (3) increased financing costs for future capital raises given negative cash flow profile. The 3-month 58% rally likely reflects rate stabilization expectations rather than fundamental improvements.
Moderate - While Alector doesn't rely on credit markets for operations, the company's survival depends on accessing equity or debt capital markets given $200M annual cash burn. Tightening credit conditions reduce biotech IPO/follow-on activity and increase dilution risk for existing shareholders. Partnership economics with GSK/AbbVie provide some insulation, but clinical failures could force distressed financing.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from clinical trial catalysts. The 58% 3-month rally followed by negative 6-month return reflects high-beta momentum trading around binary events. Not suitable for value or income investors given negative earnings, no dividends, and balance sheet stress. Institutional ownership likely concentrated among specialized healthcare hedge funds with expertise in clinical trial probability modeling.
high - Clinical-stage biotechnology stocks exhibit extreme volatility around data readouts, with single-day moves of 30-50% common on trial results. Small market cap ($0.2B) amplifies price swings from modest order flow. Implied volatility likely exceeds 80-100% around key catalysts. The 14.2% 1-year return masks multiple 40%+ intra-year drawdowns typical for pre-revenue biotech.
